Do retina transplants represent the future of retinal degeneration treatment?

Article

Transplants of foetal retinal cells are an effective treatment for retinal degeneration involving the destruction of photoreceptor cells, according to a report published in the August 2008 issue of the American Journal of Ophthalmology.

Transplants of foetal retinal cells are an effective treatment for retinal degeneration involving the destruction of photoreceptor cells, according to a report published in the August 2008 issue of the American Journal of Ophthalmology.

Norman D. Radtke, MD, PSC of the University of Louisville, Kentucky, US and colleagues transplanted human foetal retinal cells (with retinal pigment epithelium) into six subjects with retinitis pigmentosa (RP) and into four subjects with dry age-related macular degeneration (AMD). No subjects, even those with immunological mismatches between donor and recipient, rejected the transplanted cells.

Seven (RP, n=3; AMD, n=4) of the 10 subjects registered significant objective visual improvement, although all remained within the “legally blind” range. One RP patient, who was treated in one eye only, maintained visual improvement and demonstrated a 27% improvement in light sensitivity in the treated eye at six years, while the untreated eye continued to deteriorate. Nevertheless, two subjects demonstrated visual improvement in untreated eyes.

Although the results of this Phase II trial have been positive, researchers acknowledge that more research must be conducted to establish if these transplants are viable as a therapy for vision improvement in eyes with these degenerative diseases of the retina.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.